SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who started this subject9/25/2000 4:52:38 AM
From: nigel batesRead Replies (1) of 4974
 
GENMAB A/S ANNOUNCES IPO PRICE RANGE AND PUBLICATION OF OFFERING CIRCULAR
Copenhagen, Denmark - Genmab A/S, an innovative biotechnology company using transgenic mouse technology to create and develop fully human antibodies to treat a wide variety of life threatening and debilitating diseases, today announced the price range for the Global Offering of 6,000,000 ordinary shares.
UBS Warburg is acting as global co-ordinator and bookrunner to Genmab in connection with the Global Offering and Carnegie Bank and Commerzbank are acting as co-lead managers.
Key Highlights:
Genmab's ordinary shares will be listed on the Copenhagen Stock Exchange and the Frankfurt Stock Exchange for trading on the Neuer Markt.
The Global Offering consists of an issue of 6,000,000 new ordinary shares delivered either in the form of ordinary shares for trading on the Copenhagen Stock Exchange or in the form of Co-Ownership Interests ("COIS") for trading on the Neuer Markt.
Each COIS will represent one ordinary share.
In addition, an over-allotment option of up to 900,000 ordinary shares has been granted to UBS Warburg.
The offer price for the Global Offering is expected to be between DKK250 and DKK300 per ordinary share and between e34 and e40 per COIS.
This equates to an offer size of DKK1,650.0 million (e221.2 million) at the mid-point of the range.
Based on an offer price at the mid-point of the price range, the market capitalisation of Genmab following the Global Offering would be approximately DKK5,998.3 million (e804.3 million) (before exercise of the over-allotment option).
Lisa N....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News